Clinical Trial Update: CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene [Phase 1]

View source ↗

Summary

Phase 1 clinical trial of CASPALLO allodepleted T cells engineered with an inducible caspase-9 suicide gene; the study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Chronic Myeloid Leukemia
• Myelodysplastic Syndrome
• Non-hodgkin Lymphoma

Drugs mentioned

• CASPALLO Allodepleted T Cells (Allodepleted T cells transduced with inducible caspase-9 suicide gene)

Snippet

Sponsor: Baylor College of Medicine | Conditions: Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING